Table 3.

Mean Number of Reported Antihypertensive Medications for Phase 2 Participants by Weight Change Group

	Weight Loss	Weight Stable	Weight Gain
Phase 1 entry	1.8±0.9	1.9±0.9	1.8±0.8
No.	54	131	462
Phase 2 entry	1.7±0.8	1.9±0.9	1.8±0.8
No.	54	127	447
Phase 3 entry	1.9±0.8	2.0±0.9	1.9±0.8
No.	50	122	403
Phase 3 end	2.2±0.9	1.9±0.9	2.0±0.9
No.	41	92	326

Values are expressed as mean±standard deviation. Values do not include imputed data.